Sign In
Buy ACR
$19.09
-1.30 (-6.38%)
At Close: Jun 03, 2026
Company to host conference call and webcast at 8:30 a.m. ET on Thursday, January 8, 2026 Company to host conference call and webcast at 8:30 a.m. ET on Thursday, January 8, 2026
ACRES Commercial Realty (NYSE:ACR) Major Shareholder Eagle Point Credit Management Sells 5,000 Shares of Stock
05:25am, Tuesday, 06'th Jan 2026
ACRES Commercial Realty Corp. (NYSE: ACR - Get Free Report) major shareholder Eagle Point Credit Management sold 5,000 shares of the business's stock in a transaction on Wednesday, December 31st. The
ACRES Commercial Realty Corp. (NYSE:ACR) Given Average Recommendation of “Moderate Buy” by Analysts
03:30am, Saturday, 20'th Dec 2025
Shares of ACRES Commercial Realty Corp. (NYSE: ACR - Get Free Report) have received an average recommendation of "Moderate Buy" from the five ratings firms that are currently covering the firm, Market
WATERTOWN, Mass., Dec. 17, 2025 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc. (“Acrivon” or “Acrivon Therapeutics”) (Nasdaq: ACRV), a clinical stage biotechnology company discovering and deve
ACRES Commercial Realty Corp. Declares Quarterly Cash Dividends for its Preferred Stock
04:10pm, Monday, 15'th Dec 2025
UNIONDALE, N.Y. , Dec. 15, 2025 /PRNewswire/ -- ACRES Commercial Realty Corp. (NYSE: ACR) (the "Company") announced today that its Board of Directors declared cash dividends on its Preferred Stock.
Contrasting Cherry Hill Mortgage Investment (NYSE:CHMI) & ACRES Commercial Realty (NYSE:ACR)
01:17am, Saturday, 13'th Dec 2025
ACRES Commercial Realty (NYSE: ACR - Get Free Report) and Cherry Hill Mortgage Investment (NYSE: CHMI - Get Free Report) are both small-cap finance companies, but which is the better investment? We wi
ACRES Commercial Realty: Book Value Expands As Buybacks Shrink Outstanding Shares
09:59am, Thursday, 11'th Dec 2025
ACRES Commercial Realty grew its book value by $1.70 per share sequentially to $29.63 during the third quarter, with the common currently swapping hands at a 20.42% discount. The mREIT bought back 153
ACR Poker's Dual Venom PKO Tournaments Deliver Knockout Success, Smashing Guaranteed Prize Pools to Award $7.8 million to Players
08:36am, Tuesday, 04'th Nov 2025
/PRNewswire/ -- ACR Poker's Dual Venom PKO tournaments have wrapped up in spectacular fashion, smashing guarantees once again, and showing why it's one of the
ACRES Commercial Realty Corp. (ACR) Q3 2025 Earnings Call Transcript
02:46pm, Thursday, 30'th Oct 2025
ACRES Commercial Realty Corp. ( ACR ) Q3 2025 Earnings Call October 30, 2025 10:00 AM EDT Company Participants Kyle K. Brengel Mark Fogel - President, CEO & Director Eldron Blackwell - CFO & Senior VP
ACRES Commercial Realty Corp. Reauthorizes an Additional $7.5 Million Share Repurchase Program
04:17pm, Wednesday, 29'th Oct 2025
UNIONDALE, N.Y. , Oct. 29, 2025 /PRNewswire/ -- ACRES Commercial Realty Corp. (NYSE:ACR) (the "Company") announced today that its board of directors (the "Board") authorized and approved the continued
ACRES COMMERCIAL REALTY CORP. REPORTS RESULTS FOR THIRD QUARTER 2025
04:10pm, Wednesday, 29'th Oct 2025
UNIONDALE, N.Y. , Oct. 29, 2025 /PRNewswire/ -- ACRES Commercial Realty Corp. (NYSE: ACR) ("ACR" or the "Company"), a real estate investment trust that is primarily focused on originating, holding an
Anaptys Announces New Positive Phase 2b Trial Results for Rosnilimab in Rheumatoid Arthritis at ACR Late-Breaking Oral Presentation
09:15am, Wednesday, 29'th Oct 2025
SAN DIEGO, Oct. 29, 2025 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced late-brea
Ness-Ziona, Israel, Oct. 28, 2025 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, today announced that
Cabaletta Bio Presents Positive Clinical Data and Development Updates for Rese-cel at ACR Convergence 2025
07:00am, Monday, 27'th Oct 2025
– All myositis patients in the Phase 1/2 DM/ASyS cohort with sufficient follow-up who met key registrational inclusion criteria exceeded the registrational primary endpoint, demonstrating major TIS
Tonmya demonstrated significant reduction in fibromyalgia pain compared with placebo in the Phase 3 RESILIENT study Treatment was well tolerated with minimal effects on weight or blood pressure and di
